Description:This study is looking at the safety and effectiveness of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/Mk-7902).
Group A: Pembrolizumab and lenvatinib
Intervention: Pembrolizumab is an immunotherapy drug that will help immune system cells to attack and get rid of cancer cells. Lenvatinib is a targeted chemotherapy drug that is a tyrosine kinase inhibitor. It slows down or stops the growth of cancer cells.
Can I consider participating?
YES: patients who have a metastatic and/or unresectable solid tumor that is uncurable, has received 2 prior lines of therapy
NO: patients who have gastrointestinal condition, active infection or autoimmune disease